52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
Neolignans from the Arils of Myristica fragrans as Potent Antagonists of CC Chemokine Receptor 3.
Kindai University
35
Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model.
Boehringer Ingelheim Pharma
23
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.
AstraZeneca
30
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: optimising in vivo clearance.
AstraZeneca
67
Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.
Bristol Myers Squibb
52
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
AstraZeneca
28
Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.
Toray Industries
21
Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.
Astellas Pharma
19
Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists.
Astellas Pharma
49
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.
Bristol Myers Squibb
21
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.
Novartis Institutes For Biomedical Research
10
Design and synthesis of a library of chemokine antagonists.
Novartis Institutes of Biomedical Research
14
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.
Telik
37
Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.
Astellas Pharma
20
Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Bristol Myers Squibb
26
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Roche Palo Alto
11
Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.
Bristol Myers Squibb
37
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.
Bristol Myers Squibb
77
Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).
Bristol Myers Squibb
58
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.
Bristol Myers Squibb
25
2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.
Bristol Myers Squibb
26
Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.
Merck Research Laboratories
11
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Takeda Pharmaceutical
23
The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists.
Schering-Plough Research Institute
62
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
Pharmaceutical Research Institute
91
Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.
Biographics Laboratory 3R
46
The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists.
Schering-Plough Research Institute
35
N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Dbristol-Myers Squibb
31
Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators.
Boehringer Ingelheim Pharma Gmbh And
37
Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.
Bristol Myers Squibb
5
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
University of Florida
109
Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.
Bristol Myers Squibb
87
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.
Bristol Myers Squibb
19
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.
Merck Research Laboratories
16
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.
Merck Research Laboratories
38
Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2.
Smithkline Beecham Pharmaceuticals
27
Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1.
Smithkline Beecham Pharmaceuticals
33
Design, synthesis, and discovery of a novel CCR1 antagonist.
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
47
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.
Merck Research Laboratories
24
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
Takeda Chemical Industries
68
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.
Gsk Pharmaceuticals R & D
